CA3183881A1 - Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof - Google Patents
Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereofInfo
- Publication number
- CA3183881A1 CA3183881A1 CA3183881A CA3183881A CA3183881A1 CA 3183881 A1 CA3183881 A1 CA 3183881A1 CA 3183881 A CA3183881 A CA 3183881A CA 3183881 A CA3183881 A CA 3183881A CA 3183881 A1 CA3183881 A1 CA 3183881A1
- Authority
- CA
- Canada
- Prior art keywords
- xyl
- rha
- saponin
- fuc
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2025902 | 2020-06-24 | ||
| NL2025902 | 2020-06-24 | ||
| PCT/NL2021/050384 WO2021261992A1 (en) | 2020-06-24 | 2021-06-18 | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate |
| NLPCT/NL2021/050384 | 2021-06-18 | ||
| PCT/NL2021/050394 WO2021261998A1 (en) | 2020-06-24 | 2021-06-23 | Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3183881A1 true CA3183881A1 (en) | 2021-12-30 |
Family
ID=76601666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3183881A Pending CA3183881A1 (en) | 2020-06-24 | 2021-06-23 | Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230293562A1 (https=) |
| EP (2) | EP4596052A3 (https=) |
| JP (1) | JP2023533693A (https=) |
| KR (1) | KR20230044196A (https=) |
| CN (1) | CN116194148A (https=) |
| AU (1) | AU2021296983A1 (https=) |
| CA (1) | CA3183881A1 (https=) |
| IL (1) | IL299349A (https=) |
| WO (1) | WO2021261998A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260025101A (ko) * | 2023-06-02 | 2026-02-23 | 사프렘 테크놀로지스 비.브이. | 세포내 분자 표적을 통해 작용하는 치료적 이펙터 성분을 위한 개선된 치료 요법 |
| WO2025155911A1 (en) | 2024-01-18 | 2025-07-24 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of hurler syndrome |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011054811A1 (en) * | 2009-11-03 | 2011-05-12 | Santaris Pharma A/S | Rna antagonists targeting hsp27 combination therapy |
| MX2016005855A (es) * | 2013-11-14 | 2016-07-13 | Roche Innovation Ct Copenhagen As | Compuestos de conjugados antisentido de apolipoproteina b (apob). |
| SG11202106603UA (en) * | 2018-12-21 | 2021-07-29 | Sapreme Tech Bv | Biologically active cluster of molecules |
-
2021
- 2021-06-23 AU AU2021296983A patent/AU2021296983A1/en active Pending
- 2021-06-23 EP EP25178184.5A patent/EP4596052A3/en active Pending
- 2021-06-23 WO PCT/NL2021/050394 patent/WO2021261998A1/en not_active Ceased
- 2021-06-23 EP EP21734544.6A patent/EP4171643B1/en active Active
- 2021-06-23 CA CA3183881A patent/CA3183881A1/en active Pending
- 2021-06-23 IL IL299349A patent/IL299349A/en unknown
- 2021-06-23 KR KR1020237002644A patent/KR20230044196A/ko active Pending
- 2021-06-23 US US18/012,778 patent/US20230293562A1/en active Pending
- 2021-06-23 CN CN202180052532.8A patent/CN116194148A/zh active Pending
- 2021-06-23 JP JP2022580238A patent/JP2023533693A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4171643C0 (en) | 2025-06-04 |
| CN116194148A (zh) | 2023-05-30 |
| JP2023533693A (ja) | 2023-08-04 |
| US20230293562A1 (en) | 2023-09-21 |
| WO2021261998A1 (en) | 2021-12-30 |
| EP4596052A2 (en) | 2025-08-06 |
| EP4596052A3 (en) | 2025-11-05 |
| KR20230044196A (ko) | 2023-04-03 |
| EP4171643B1 (en) | 2025-06-04 |
| EP4171643A1 (en) | 2023-05-03 |
| AU2021296983A1 (en) | 2023-02-23 |
| IL299349A (en) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021295358B2 (en) | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate | |
| EP4355369B1 (en) | Conjugate of saponin, oligonucleotide and galnac | |
| WO2022055351A1 (en) | Conjugate of saponin, oligonucleotide and galnac | |
| WO2021261992A1 (en) | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate | |
| EP4171643B1 (en) | Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof | |
| EP4210760B1 (en) | Conjugate of saponin, oligonucleotide and galnac | |
| HK40128805A (en) | Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof | |
| HK40116734A (en) | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac oligonucleotide conjugate | |
| HK40124033A (en) | Conjugate of saponin, oligonucleotide and galnac | |
| AU2026202914A1 (en) | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate | |
| HK40110483B (en) | Conjugate of saponin, oligonucleotide and galnac | |
| HK40110483A (en) | Conjugate of saponin, oligonucleotide and galnac | |
| HK40091234B (en) | Conjugate of saponin, oligonucleotide and galnac | |
| HK40091234A (en) | Conjugate of saponin, oligonucleotide and galnac | |
| HK40129944A (zh) | Galnac和皂苷的缀合物、包含所述缀合物和galnac-寡核苷酸缀合物的治疗性组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241112 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241112 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250529 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250529 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250529 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250530 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250617 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250617 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20250711 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251202 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251202 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251202 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251209 |